Therapeutic apheresis in critically ill patients
β Scribed by Kimberly W. Sanford; Rasheed A. Balogun
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 61 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Therapeutic apheresis procedures in critically ill patients comprises of therapeutic plasma exchange in most cases but also less commonly, erythrocytapheresis (red cell exchange), thrombocytapheresis, or leukocytapheresis. These procedures present a number of challenges to the apheresis healthcare team, and there are myriad beneficial and adverse effects for patients. In this patient population, one has to weigh the risks against the benefits and especially in those situations where apheresis is requested as a treatment when other alternative therapies have failed. Therapeutic plasma exchange is capable of removing toxins, pathologic autoβ and alloβantibodies but will also remove beneficial medications, clotting factors and cations which are chelated by citrate anticoagulant. Herein, we review clinically significant issues that are commonly encountered in patients that are in the intensive care unit and have conditions that require therapeutic apheresis. J. Clin. Apheresis 2011. Β© 2011 WileyβLiss, Inc.
π SIMILAR VOLUMES
The purpose of this paper is to obtain empirical measures of performance in the management of critical patients treated in intensive care units (ICUs) and to evaluate the factors associated with performance, in a two stage approach. In the first stage, this paper uses an extended version of Data Env
Apheresis procedures in critically ill patients present a number of challenges to the apheresis team and there are myriad beneficial and adverse effects on patients. Plasmapheresis using a 1 blood volume exchange removes up to 63% of plasma solutes, whereas an exchange using 1.5 blood volumes will r
Dr. Hamburger was asked whether he would recommend the use of cytoxin or lymphacytapheresis first in the treatment of rheumatoid arthritis. He stated that he would recommend lymphacytapheresis first, especially in relatively young patients because of the multiple side effects and the risk of long-te